Tvardi Therapeutics Reports Q3 2026 Net Loss of $6.1 Million

Tvardi Therapeutics reported a Q3 2026 net loss of $6.1M, up from $5.5M a year earlier. R&D expenses rose to $4.5M, while G&A expenses fell to $1.9M. The company had $22.3M in cash and expects funds to last into Q3 2027. Tvardi is preparing to advance TTI-109 into clinical trials for ulcerative colitis and expects Phase 1b/2 REVERT LIVER CANCER study results in early Q1 2027.

Original reporting
Published Nov 13, 2026, 12:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 12:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tvardi Therapeutics Reports Q3 2026 Net Loss of $6.1 Million — source image
Decision brief

The 30-second read

$TVRDBearishMed
01

Why it matters

The earnings release highlights a widening loss but also progress in its pipeline, which may influence short‑term trading sentiment.

02

Market read

Micro‑cap biotech earnings with modest cash runway and pipeline updates; likely short‑term downside pressure.

03

What to watch

Potential non‑dilutive funding sources or partnership deals not disclosed in the filing.

Relevance 7/10Novelty 7/10Timing: post‑earnings release today

Background

Tvardi Therapeutics is a clinical‑stage biotech focusing on STAT3 inhibition for inflammatory diseases and liver cancer.

Company-level read

Ticker impact

$TVRDBearishMedium confidence
Context

Tvardi Therapeutics disclosed its Q3 2026 earnings, reporting a net loss of $6.1 million and cash balance of $22.3 million.

Expected impact

likely downward pressure as investors digest the loss and limited cash runway

Evidence & confidence

Earnings miss and cash constraints typically weigh on micro‑cap biotech shares, while pipeline progress may limit the decline.

Market effects

Biotech sector may see modest pullback as micro‑cap earnings miss, but pipeline news could buoy peers focused on ulcerative colitis and liver cancer.

US biotech investors may adjust exposure to early‑stage companies with limited cash.

Limited to investors tracking small‑cap biotech pipelines.

Counterpoint

If the upcoming TTI‑109 trial data exceeds expectations, the stock could rebound sharply despite the loss.

Key entities

  • Tvardi Therapeutics

    Clinical‑stage biotech reporting Q3 2026 results.

Related articles

$TVRDMed

Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update

Tvardi Therapeutics, Inc. (TVRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update HOUSTON, TX – November 13, 2026 – Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of

$TVRDMed

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Tvardi Therapeutics, Inc. (TVRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immu

$TVRDMedAI 8/10

Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109

Tvardi Therapeutics (NASDAQ: TVRD) reported Phase 1 results for its oral STAT3 inhibitor TTI-109. The company said TTI-109 rapidly converts to TTI-101, shows dose-proportional pharmacokinetics with exposures above the STAT3 IC50, and reduced STAT3-driven immune cell populations by up to 60% in exploratory analyses. It also cited shorter diarrhea duration vs TTI-101. TVRD shares rose sharply on the news.

$TVRDMed

Tvardi's TTI-109 Shows Improved Tolerability And Target Engagement In Phase 1 Study

Tvardi Therapeutics (TVRD) reported Phase 1 results for TTI-109, a phosphate prodrug of TTI-101. The drug converted rapidly and showed plasma exposure similar to TTI-101 at equivalent doses, with repeat dosing maintaining levels above the STAT3 inhibitory threshold for 21 days. Exploratory data showed up to 60% reductions in STAT3-driven immune cells and shorter diarrhea duration vs TTI-101. Phase 2 is planned pending funding.

$TVRDMedAI 8/10

Why Is Tvardi Therapeutics Stock Gaining Tuesday? - Tvardi Therapeutics (NASDAQ:TVRD)

Tvardi Therapeutics (NASDAQ:TVRD) reported Phase 1 results for TTI-109, a STAT3 inhibitor prodrug. The company said TTI-109 converted to TTI-101 within two hours, showed dose-proportional pharmacokinetics and target engagement, and had diarrhea events comparable to placebo (0.46 vs 3.35 days vs near-equivalent TTI-101). Shares rose ~49.75% to $3.01; plans to advance into dermatologic and gastrointestinal indications pending IND clearance and funding.